Xilio Therapeutics, Inc. 8-K

What Happened
Xilio Therapeutics, Inc. (XLO) announced on April 15, 2026 (Item 5.02 in an 8-K) that the Board elected Cheryl R. Blanchard, Ph.D., as a Class III director, with a term expiring at the company’s 2027 annual meeting. Dr. Blanchard was also named chair of the Compensation Committee and a member of the Audit Committee. She succeeds Christina Rossi, who resigned effective April 15, 2026; the company said Rossi’s resignation was not due to any disagreement with management.

Key Details

• Dr. Blanchard’s board term: Class III director, term through the 2027 annual meeting.
• Cash compensation: $40,000 annually for Board service, plus $12,000 annually as Compensation Committee chair and $7,500 annually as an Audit Committee member.
• Equity awards: initial option to purchase 10,000 shares (vests one‑third annually over 3 years); eligible after 6 months for an annual option for 5,000 shares (vesting earlier of one year or immediately prior to next annual meeting). Options expire 10 years after grant; exercise price = Nasdaq closing price on grant date.
• Governance/legal: Dr. Blanchard will enter the company’s standard indemnification agreement.

Why It Matters
Board composition and committee leadership affect corporate oversight—appointing a new Compensation Committee chair is directly relevant to executive pay and governance oversight. The disclosed cash and equity compensation are standard for non‑employee directors but include equity awards that, if exercised, could modestly increase share count. The resignation of the prior director was described as routine and not related to any dispute with management.